Navigation Links
Genedata Announces Collaboration With AstraZeneca on the Analysis of Compound Combination Experiments
Date:12/3/2013

Basel, Switzerland (PRWEB) December 03, 2013

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced its successful collaboration with AstraZeneca on data analysis for compound combination experiments. Drug combination studies, which are increasingly used in pre-clinical research, produce large volumes of data with upwards to 200 combinations per experiment. Genedata Screener, which has been proven to work as an easy and efficient platform for analyzing compound screening, has been advanced through the AstraZeneca collaboration as Genedata Screener now automates and standardizes the analysis of compound combination experiments.

“With Genedata, we are able to extract the highest value possible from our compound combination experiments,” noted Dr. Eric Tang, associate principle scientist at AstraZeneca. “Typically, compound combination experiments compare 50 or more compounds across a number of cell lines in a single study, resulting in the analysis of hundreds of 384/1536 well plates. Genedata Screener can handle these large data sets and enable us to generate and compare results for the same compound combinations in different cell lines, and review alternative analysis for the same data sets. Moreover, Screener helps standardize data analysis giving us more quality time to conduct detailed analysis,” continued Dr. Tang.

From Raw Data to Synergy Scores in Minutes
Combination therapies – the simultaneous use of a variety of drugs to treat a range of diseases from infections to cancer – have gained importance as a cure. And, compound combination experiments are a resurging trend in lead optimization and target validation. Data sets from these experiments tend to be large, as the number of measurements scales exponentially with the number of compounds to be compared. Genedata Screener effectively addresses the data analysis challenges of these large data sets by enabling researchers to:

  • Go from raw data to results in less than 30 minutes, also for large studies
  • Eliminate time-consuming manual data processing
  • Interactively inspect raw data and check the quality of normalized values
  • Review in-depth intermediate and final results using combination-specific displays such as concentration matrices and isobolograms
  • Automatically fit both mono-therapeutic and combination dose-response curves for quick and robust results
  • Display, quantify and compare measured and expected combination effects for different interaction models such as Loewe, Highest Single Agent, or Bliss
  • Access all processing steps throughout the workflow
“We see a huge demand for software that efficiently analyzes compound combination experiments in novel drug discovery,” said Dr. Othmar Pfannes, CEO of Genedata. “Our successful collaboration with AstraZeneca, a leader in combination therapies, helps us to further advance Genedata Screener as the platform of choice for the efficient analysis of compound combination experiments.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US. http://www.genedata.com.

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at http://www.prweb.com/releases/2013/11/prweb11324964.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biogas Consortium Using Genedata Selector for Metagenomics-based Process Optimization
2. Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
3. Evonik and Genedata Broaden Their Collaboration with the Genedata Selector Biotechnology Data Management Platform
4. Genedata Screener Global User Group Meetings Will Examine Advancements in Plate-based Screening
5. Genedata Screener Extends Support for High-Throughput Thermofluor Assays
6. Genedata at ESACT Announces Expansion Into Biopharma Process Development
7. New Genedata Expressionist for Mass Spectrometry Showcases at 2013 ASMS
8. AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization
9. Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
10. Genedata Screener 11 with Compound Combination Screening and Collaboration in the Cloud Announced at Bio-IT World 2013
11. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... (CRO) has validated a 0.2 ng/mL lower limit (LLOQ) assay for nicotine and ... ng/mL LLOQ assay, the ultra-low trace nicotine assay meets additional needs of tobacco ...
(Date:4/27/2017)... ... April 27, 2017 , ... This month ... (eConsent) solution that simplifies research studies, accelerates study startup, and improves participant engagement. ... Consent™ is the first and only IRB-integrated eConsent solution . , “Our ...
(Date:4/27/2017)... Washington, USA (PRWEB) , ... April 27, 2017 ... ... for optics and photonics , joined other scientists, researchers, engineers, and industry professionals ... measures to strengthen America's ability to compete in the world photonics industry. , ...
(Date:4/26/2017)... Myrtle Beach, SC (PRWEB) , ... April 26, ... ... for the mind, has teamed up with NASA to showcase the future of ... NASA’s Space Launch System (SLS) rocket and Orion spacecraft and includes a guest ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):